FAM47A: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Target Name: FAM47A

NCBI ID: G158724

FAM47A

Other Name(s): Protein FAM47A | Family with sequence similarity 47 member A | FA47A_HUMAN | MGC27003 | family with sequence similarity 47 member A

FAM47A: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Introduction

Neurodegenerative disorders are a group of progressive diseases that affect the nervous system, leading to a range of symptoms and impairments. These disorders are often characterized by the progressive loss of brain cells, leading to the development of neurofibrillary tangles and the formation of neuroglial plaques. FAM47A, a protein that has been identified as a potential drug target and biomarker for neurodegenerative disorders, has been shown to play a critical role in the development and progression of these disorders.

FAM47A: Structure and Function

FAM47A is a member of the FAM (FAMILY member) domain family, which is characterized by the presence of af glycine side chains and a core alpha helix. FAM47A has a unique structure, with a 100 amino acid long carboxy-terminal tail and a 20 amino acid long N-terminus. FAM47A also has a unique post-translational modification, with a 纬-glutamyl transferase (GST) and a 45KDa calbindinyl- histone (CBH) association.

FAM47A has been shown to play a critical role in the development and progression of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Studies have shown that overexpression of FAM47A has been associated with the development of neurodegenerative disorders, while inhibition of FAM47A has been shown to protect against these disorders.

Drug Target Potential

FAM47A has been identified as a potential drug target for neurodegenerative disorders due to its unique structure and function. The 纬-glutamyl transferase (GST) activity of FAM47A has been shown to contribute to its neurotoxicity, as it has been shown to increase the production of reactive oxygen species (ROS) in brain cells. The CBH association of FAM47A has also been shown to contribute to its neurotoxicity, as it has been shown to increase the production of pro-inflammatory cytokines in brain cells.

In addition to its neurotoxicity, FAM47A has also been shown to play a critical role in the regulation of cellular signaling pathways, including the JNK pathway. The JNK pathway is a signaling pathway that plays a critical role in the regulation of cellular stress responses, and has been implicated in the development of neurodegenerative disorders.

Biomarker Potential

FAM47A has also been shown to have potential as a biomarker for neurodegenerative disorders. The GST activity of FAM47A has been shown to be associated with the production of ROS in brain cells, which can be used as a marker for neurodegeneration. In addition, the CBH association of FAM47A has been shown to be associated with the production of pro-inflammatory cytokines in brain cells, which can also be used as a marker for neurodegeneration.

Conclusion

FAM47A is a protein that has been identified as a potential drug target and biomarker for neurodegenerative disorders. Its unique structure and function, including its GST and CBH associations, make it an attractive target for drug development. Further studies are needed to fully understand the role of FAM47A in the development and progression of neurodegenerative disorders, as well as its potential as a biomarker for these disorders.

Protein Name: Family With Sequence Similarity 47 Member A

The "FAM47A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM47A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets